StockMarketWire.com - Drug development company Evgen Pharma said all necessary regulatory approvals had now been received to carry out a clinical trial at the end of the month of its lead drug to treat acute respiratory infections in patients with suspected COVID-19.

STAR, phase II/III trial would investigate whether the company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome.



At 9:21am: [LON:EVG] Evgen Pharma Plc share price was +1.25p at 13.63p



Story provided by StockMarketWire.com